Farmaceutica, Chinni (Ucb): “AI centrale, terapie digitali vera novità”
(Adnkronos) - “L’intelligenza artificiale sta cambiando radicalmente i processi e l'approccio al lavoro anche nel settore healthcare e in quello farmaceutico, dove le opportunità che offre sono davvero tantissime. Se penso al mondo dell'industria farmaceutica credo che tutti abbiamo delle opportunità molto importanti. E quando dico molto importanti, mi riferisco ovviamente alla capacità dell'AI di portare all'interno dei trial clinici sempre più molecole e sempre più candidabili ad essere portate con successo sul mercato". Così Federico Chinni, amministratore delegato di Ucb Italia, in occasione dell'evento “Intelligenza Artificiale, Rischi e Opportunità” organizzato oggi da Adnkronos a Palazzo dell'Informazione.
Category
🗞
NewsTranscript
00:00 What are the opportunities in the pharmaceutical industry?
00:07 There are many opportunities in our sector.
00:11 If I think about the pharmaceutical industry,
00:14 I think there is a very important opportunity.
00:18 When I say "very important", I mean the ability
00:22 to bring more and more molecules into trial clinics
00:26 and more and more molecules that can be successfully brought to the market.
00:32 Today, the pharmaceutical industry is the sector that invests the most in research and development.
00:37 1,600 billion, for example, in the fifth quarter 2021-2026.
00:41 But unfortunately, we do not have a linearity between investments
00:45 and all the molecules that can be successfully brought to the market.
00:50 In this area, artificial intelligence can help a lot.
00:54 Thanks to its computational capacity, it can help reduce the time
00:59 of preclinical selection of molecules,
01:02 calculating and therefore identifying those that will be most successful
01:07 compared to the trial clinic, with which they will have to verify their effectiveness
01:12 and above all their degree of safety.
01:15 Digital therapies are a novelty in the world of pharmacological treatment
01:21 because they are actually assimilable to a drug,
01:25 because like a drug they can have benefits compared to specific treatment outcomes.
01:30 But unlike a drug, they do not have a molecule, but they have a software.
01:34 They can be in various forms, they can be an app, a web-based application,
01:38 even a video game, which thanks to the ability to improve certain patient behaviors
01:46 can also guarantee an improvement of specific treatment outcomes.
01:50 I'll give you a data.
01:52 One of the very important documents in our field is what was published by the WHO,
01:59 that is the World Health Organization, compared to the health determinants,
02:03 that is, what makes us feel good or what affects our health.
02:07 It is said that about 20% of these determinants are made up of the treatments,
02:11 that is, the doctor who treats us, the drug we take,
02:15 the therapies or diagnostic tests we perform.
02:18 But 20-30% is connected instead to our behaviors,
02:22 so our lifestyle, diet, positive thinking, stopping smoking.
02:26 All these things can have a very important impact on the treatment outcomes.
02:31 So digital therapies, thanks to those mechanisms I described before,
02:36 can have an impact on these specific determinants.
02:39 Artificial intelligence manages to work and produce its positive effects
02:45 when it can count on a very important amount of data,
02:49 from a quantitative point of view, but also from a qualitative point of view.
02:53 I believe that our country has today,
02:55 also thanks to the resources provided by the PNRR,
02:59 an extraordinarily important opportunity,
03:02 which is that of the electronic health record, for example,
03:05 that is, the possibility for all citizens to have a document
03:09 in which they can store, therefore insert and store, our data.
03:14 Only with this ability, and above all to make data interoperable,
03:19 that is, manageable through different platforms,
03:22 we can really fully exploit all the potential of artificial intelligence.